Amicus Therapeutics

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Amicus Therapeutics reports robust revenue growth and eyes AT-GAA launch

Amicus Therapeutics showcased strong performance and growth prospects for Galafold and AT-GAA therapy.
The company aims for non-GAAP profitability in 2023, focusing on key strategic priorities and market expansion.
Challenges include profitability targets, regulatory approvals, and managing production costs for new therapies.
Opportunities lie in the anticipated AT-GAA launch, geographic market expansion, and continued revenue growth.

Amicus Therapeutics reports robust Q1 performance and eyes AT-GAA FDA approval

Amicus Therapeutics delivered strong Q1 results, focusing on revenue growth, regulatory milestones, and financial stability. The company's strengths lie in Galafold sales growth, positive patient outcomes with AT-GAA, and market opportunities in Pompe disease treatment. Challenges include scaling up patient numbers and transitioning manufacturing facilities, while opportunities exist in market expansion and physician engagement.

Amicus Therapeutics excels in Q2, eyes global expansion and profitability

Amicus Therapeutics demonstrates strong financial growth, focusing on expanding market presence and achieving non-GAAP profitability. The company's performance with Galafold and progress on regulatory filings position it well for future success, despite facing challenges in patient transitions and leadership changes.

Amicus Therapeutics reports robust Q3 earnings and growth opportunities

Amicus Therapeutics delivered strong financial results in Q3 2023, with revenue growth and profitability on track, supported by strategic investments and market expansion efforts.
The company's focus on patient-centric approaches, physician engagement, and global market penetration positions it well for future growth and success.
While facing challenges in gene therapy programs and revenue dynamics, Amicus is actively addressing these issues and leveraging opportunities in expanding markets and innovative therapies.
Overall, Amicus Therapeutics remains well-positioned in the biopharmaceutical industry, with a strong foundation for continued growth and impact in treating rare diseases.

Amicus Therapeutics reports strong Q4 earnings and growth opportunities

Amicus Therapeutics delivered strong financial results in Q4 2023, aiming for sustained growth and profitability in 2024 through strategic priorities and successful product launches.
The company faces challenges in forecasting seasonal trends and expanding payer coverage, yet opportunities lie in maximizing patient therapy, leveraging AI advancements, and broadening market reach.
With a focus on rare disease treatments and market penetration, Amicus is poised for growth and intervention strategies to address patient variability and drive revenue in 2024.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?

Why Is Amicus Therapeutics (FOLD) Up 6% Since Last Earnings Report?

As of late, it has definitely been a great time to be an investor in Amicus Therapeutics, Inc. (FOLD).

Amicus Therapeutics, Inc. (FOLD) Shares March Higher, Can It Continue?

Bloom Energy

Kinross Gold

NeoPhotonics

Teekay Tankers

How to Find Cheap Buy-Ranked Stocks Trading Under $10

Amicus (FOLD) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

Amicus' (FOLD) Shares Rise on Q3 Earnings & Revenue Beat

Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q3 2019 Results - Earnings Call Transcript

What Makes Amicus Therapeutics An Exciting Buy Now

New Data Support Meaningful Impact on Motor and Language Function in Children with Fatal Neurologic Disease

Amicus Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 48th Annual Meeting of the Child Neurology Society

The gene therapy stock is trading at its lowest level in over two years. It recently announced preliminary third-quarter 2019 operating results.

Is Amicus Therapeutics a Buy?

Analyst Day 2019 to Highlight Financial Outlook and    Robust Portfolio of Novel Therapies for Rare Metabolic Diseases

Amicus Therapeutics Announces Preliminary Third Quarter 2019 Revenue and Financial Outlook at 2019 Analyst Day

The competitive outlook for a key therapy is worrying investors.

Why Amicus Therapeutics Stock Folded in September

Persistent and Durable Responses Across Safety, Functional Outcomes and Biomarkers for ERT-Naïve and ERT-Switch Patients in Cohorts 1, 2 and 3 Out to Month 24

Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study of AT-GAA at the 24th International Annual Congress of the World Muscle Society

CRANBURY, N.J., Oct.  01, 2019  (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following medical and investor conferences in October.

Amicus Therapeutics to Present at Upcoming Medical and Investor Conferences in October 2019

Investor concerns over the competitive outlook for the company's Pompe disease therapy candidate weighed on its stock price.

Why Amicus Therapeutics Tanked in August

Why Is Amicus Therapeutics (FOLD) Down 18.9% Since Last Earnings Report?

CRANBURY, N.J., Sept.  04, 2019  (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following investor conferences in September.

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2019

Vertex Pharmaceuticals

Allakos Inc

Biohaven Pharmaceutical Hld

Jazz Pharmaceuticals

Golden crosses and death crosses are common signals in technical analysis and refer to the relationship between short-term and long-term moving averages.

Vertex Pharmaceuticals and Other Biotech Stocks With Recent Golden Crosses

Amicus was able to achieve positive interim results from a phase 1/2 study using AAV-CLN6 gene therapy to treat patients with Batten disease.

Amicus Should Be On Your Radar As It Makes Progress On Multiple Fronts Using Gene Therapy

Amicus' (FOLD) earnings meet estimates in the second quarter while revenues beat the same.

Amicus (FOLD) Q2 Earnings Match, Stock Falls on Weak Q3 View

Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q2 2019 Results - Earnings Call Transcript

Amicus' shares shot up by 10.7% last month. Here's why.

Why Amicus Therapeutics' Stock Perked Up in June

Why Is Amicus Therapeutics (FOLD) Down 9.6% Since Last Earnings Report?

Amicus expands license agreement deal with University of Pennsylvania to develop a host of gene therapies for rare diseases.

Amicus Looks To Push Gene Therapy Pipeline After Latest Expanded Agreement

Earnings and other concerns held some stocks back Thursday.

Why NIO, PVH, and Amicus Therapeutics Slumped Today

The company announced a significant stock offering.

Here's Why Amicus Therapeutics Fell as Much as 15.6% Today

Pfizer

Amicus Therapeutics and Array BioPharma are two top growth stocks to consider buying now.

News for Amicus Therapeutics Stock (FOLD)